Aureka Biotechnologies has successfully completed a Series A financing round worth tens of millions of US dollars, led by Matrix Partners China and Qiming Venture Partners, alongside existing investors Newlight Capital and Agentic Ventures. The funds will enhance their R&D pipelines, advancing them into critical clinical stages and enabling broader collaborations within the biopharmaceutical sector.
The company specializes in generative antibody drug development, leveraging three core technology platforms to redefine drug design through autonomous agents. This innovative approach significantly improves efficiency, enabling the screening of 10-20 antibody pipelines annually, compared to traditional methods.
Aureka’s unique methodologies, such as constructing large-scale combinatorial libraries, allow for higher molecular diversity and targeted design—challenges traditional methods struggle with. Collaborating with European and American pharmaceutical companies, Aureka is focused on addressing complex targets in autoimmune and metabolic diseases, positioning itself as a market leader in digital biotechnology.
Source link